Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8302	Companies
115129	Keywords
55450	Articles
62533	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 08/07/2024 at 06:55, 3 months 14 days ago

Formycon Announces Conference Call on 2024 Half-Year Results and Investor Conference Participation

Conference Call Investor Conferences Formycon AG Half-year Results Financial Outlook
PRESS RELEASE

published on 08/07/2024 at 06:50, 3 months 14 days ago

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Formycon schedules conference call on 2024 half-year results and confirms participation in investor conferences. Details on webcast and management presentations

Financial Results Conference Call Investor Conferences Biosimilars Formycon
BRIEF

published on 08/06/2024 at 12:45, 3 months 15 days ago

Formycon AG augmente ses perspectives pour l'exercice 2024

Exercice 2024 Formycon AG EBITDA Ajusté Biosimilaires Fonds De Roulement
BRIEF

published on 08/06/2024 at 12:45, 3 months 15 days ago

Formycon AG Increases 2024 Fiscal Year Outlook

Adjusted EBITDA Working Capital Fiscal Year 2024 Formycon AG Biosimilars
PRESS RELEASE

published on 08/06/2024 at 12:40, 3 months 15 days ago

EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
Formycon AG increases its 2024 fiscal year outlook based on positive Lucentis biosimilar performance, adjusting EBITDA and working capital forecasts

Adjusted EBITDA Working Capital Formycon AG 2024 Fiscal Year Lucentis Biosimilar
BRIEF

published on 07/30/2024 at 06:55, 3 months 22 days ago

Formycon commence l'essai clinique de phase III pour le biosimilaire Keytruda® FYB206

Essais Cliniques Formycon Biosimilaire FYB206 Keytruda
BRIEF

published on 07/30/2024 at 06:55, 3 months 22 days ago

Formycon Begins Phase III Clinical Trial for Keytruda® Biosimilar FYB206

Clinical Trials Biosimilar Formycon FYB206 Keytruda
PRESS RELEASE

published on 07/30/2024 at 06:50, 3 months 22 days ago

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda

Formycon AG NSCLC Phase III Trial FYB206 Keytruda Biosimilar
BRIEF

published on 07/26/2024 at 12:05, 3 months 26 days ago

Formycon et Fresenius Kabi reçoivent un avis positif du CHMP pour FYB202 (Ustekinumab)

Formycon Fresenius Kabi FYB202 Biosimilaire Avis Du CHMP
BRIEF

published on 07/26/2024 at 12:05, 3 months 26 days ago

Formycon and Fresenius Kabi Receive Positive CHMP Opinion for FYB202 (Ustekinumab)

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion

Accesswire

Published on 11/22/2024 at 00:00, 2 hours 38 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 4 hours 33 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 4 hours 48 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 6 hours 23 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 6 hours 28 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 7 hours 37 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 8 hours 2 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 8 hours 40 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 8 hours 46 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 8 hours 46 minutes ago

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.

Les Echos

Published on 11/21/2024 at 06:58, 19 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 19 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 19 hours 40 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 6 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 7 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE